Comparison of tumor mutation burden of 300 various non-Hodgkin lymphomas using panel based massively parallel sequencing

BACKGROUND: Tumor mutation burden is an emerging biomarker for immunotherapy. Although several clinical trials for immunotherapy in lymphoma have been carried out, the mutation burden of various lymphomas is not well known yet. Thus, the objective of this study was to compare tumor mutation burden o...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Junhun, Yoon, Sang Eun, Kim, Seok Jin, Ko, Young Hyeh, Kim, Won Seog
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404326/
https://www.ncbi.nlm.nih.gov/pubmed/34461835
http://dx.doi.org/10.1186/s12885-021-08695-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404326/
https://www.ncbi.nlm.nih.gov/pubmed/34461835
http://dx.doi.org/10.1186/s12885-021-08695-7

Ejemplares similares